Scholar Rock Holding Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Scholar Rock Holding Corp. (SRRK)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A global biopharmaceutical company focused on developing monoclonal antibodies that selectively target latent growth factors for rare neuromuscular diseases. The company is transitioning from a clinical-stage to a commercial-stage organization, primarily driven by its lead candidate, apitegromab, for Spinal Muscular Atrophy (SMA).
Key Milestone: The company submitted a Biologics License Application (BLA) to the FDA in January 2025 and a Marketing Authorization Application (MAA) to the EMA in March 2025. However, in September 2025, the FDA issued a Complete Response Letter (CRL) due to cGMP deficiencies at a third-party fill-finish facility, delaying approval. The company plans to resubmit once the facility resolves these issues.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(377.9) million | $(246.3) million |
| Operating Expenses | $384.6 million | $252.1 million |
| Research & Development (R&D) | $208.4 million | $184.6 million |
| General & Administrative (G&A) | $176.2 million | $67.5 million |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $367.6 million | $437.3 million |
| Long-Term Debt (Dec 31, 2025) | $99.7 million | $50.1 million |
| Accumulated Deficit | $(1.3) billion | $(922.7) million |
Note: The company has no product revenue. Expenses increased significantly in 2025 due to commercial build-out and leadership transition costs.
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased 52.6% to $384.6 million. G&A expenses more than doubled (up 161.0%) to $176.2 million, driven by investments in commercial infrastructure, increased headcount, and $18.6 million in charges related to leadership changes.
- R&D Shift: R&D expenses rose 12.9% to $208.4 million. Costs for the lead candidate apitegromab increased by $11.5 million due to drug supply manufacturing and the initiation of the Phase 2 OPAL trial, partially offset by the completion of the Phase 3 SAPPHIRE and Phase 1 DRAGON trials.
- Debt Refinancing: In February 2026 (subsequent to year-end), the company terminated its $100 million facility with Oxford Finance and entered a new $350 million facility with Blue Owl Capital, receiving an initial $100 million term loan.
- Regulatory Setback: The FDA CRL received in September 2025 regarding manufacturing deficiencies at a third-party facility represents a significant deviation from the anticipated approval timeline, requiring a resubmission of the BLA.
Guidance, Outlook, and Risks
Outlook: Management expects 2026 to be a "transformational year" with the potential to become a commercial-stage biotech company. They anticipate regulatory approvals for apitegromab in the U.S. and Europe in 2026, pending resolution of the CRL. The company plans to launch commercially in the U.S. and Europe (starting with Germany) upon approval.
Liquidity: As of December 31, 2025, the company held $367.6 million in cash and marketable securities. Management believes this, combined with the new Blue Owl facility, is sufficient to fund operations into 2027.
Key Risks & Contingencies:
- Regulatory Approval: Approval of apitegromab is contingent on resolving cGMP deficiencies at the third-party fill-finish facility. The CRL could also impact the EMA review process.
- Commercialization: The company has no prior experience commercializing a product. Success depends on building a sales force and securing reimbursement, which is uncertain in the EU.
- Capital Requirements: The company has incurred net losses since inception and will require additional capital to complete development and commercialization.
- Intellectual Property: Several key European patents are subject to opposition proceedings at the European Patent Office (EPO).
Investor Verification Checklist
- CRL Resolution Status: Verify the timeline for the third-party fill-finish facility to resolve cGMP deficiencies and the expected date for BLA resubmission to the FDA.
- Commercial Readiness: Assess the progress of the U.S. and European commercial organization build-out and the associated burn rate.
- Debt Covenants: Review the specific covenants in the new Blue Owl financing agreement, particularly the minimum cash balance requirements.
- Patent Oppositions: Monitor the status of ongoing opposition proceedings for key European patents (EP2981822, EP3365368, EP3368069, EP4358995).
- Reimbursement Strategy: Evaluate the company's strategy for pricing and reimbursement negotiations in the EU, given the lack of historical data for muscle-targeted SMA therapies.